



PCT/GB 2003 / 005630



INVESTOR IN PEOPLE

PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

REC'D 05 FEB 2004


WIPQ PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.


Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed

Dated 22 January 2004

Best Available Copy

23DEC02 E772582-1 D03022
P01/77 00-0229688.7

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

Cardiff Road
Newport
South Wales
NP10 8QQ

1. Your reference PZ 02107

2. Patent application number
(The Patent Office will fill in this part)

0229688.7

20 DEC 2002

3. Full name, address and postcode of the or of each applicant (underline all surnames)

IMAGING RESEARCH SOLUTIONS LTD
Cyclotron Building
Hammersmith Campus
DuCane Road
London
W12 0NN

Patents ADP number (if you know it)

08177883001

If the applicant is a corporate body, give the country/state of its incorporation

United Kingdom

4. Title of the invention

SOLID-PHASE PREPARATION OF [18F]FLUOROHALOALKANES

5. Name of your agent (if you have one)

HAMMETT, Audrey, Grace, Campbell; ROLLINS, Anthony, John and
HAMMER, Catriona, MacLeod

"Address for service" in the United Kingdom
to which all correspondence should be sent
(including the postcode)

Amersham plc
Amersham Place
Little Chalfont
Buckinghamshire HP7 9NA

08189375004

Patents ADP number (if you know it)

08189375004

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country

Priority application number
(if you know it)Date of filing
(day / month / year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing
(day / month / year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:

Yes

- a) any applicant named in part 3 is not an inventor, or
- b) there is an inventor who is not named as an applicant, or
- c) any named applicant is a corporate body.

See note (d))

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form.
Do not count copies of the same document

Continuation sheets of this form

Description 12

Claim(s) 2

Abstract 0

Drawing(s) 0

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

Request for preliminary examination and search (Patents Form 9/77)

Request for substantive examination
(Patents Form 10/77)

Any other documents
(please specify)

11.



HAMMETT, Audrey, Grace, Campbell

I/We request the grant of a patent on the basis of this application.

Signature

Date

18 December 2002

12. Name and daytime telephone number of person to contact in the United Kingdom HAMMETT, Audrey 01494 542747

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- a) If you need help to fill in this form or you have any questions, please contact the Patent Office on 08459 500505.
- b) Write your answers in capital letters using black ink or you may type them.
- c) If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- d) If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- e) Once you have filled in the form you must remember to sign and date it.
- f) For details of the fee and ways to pay please contact the Patent Office.

~~DUPLICATE~~

SOLID-PHASE PREPARATION OF [¹⁸F]FLUOROHALOALKANES

The present invention relates to a process for the preparation of fluorohaloalkane compounds such as [¹⁸F]bromofluoromethane. [¹⁸F]Fluorohaloalkanes are important reagents for performing O-, N-, and S-[¹⁸F]fluoroalkylations and are commonly used to radiolabel radioligands for use in positron emission tomography (PET) studies.

[¹⁸F]Fluorohaloalkanes have previously been prepared by nucleophilic displacement, by [¹⁸F]F⁻, of a leaving group from a suitable precursor compound. Thus, for example Zhang *et al*, Applied Radiation and Isotopes 57, 335-342 (2002), describes synthesis of [¹⁸F]fluoroethyl bromide by nucleophilic displacement of 2-trifluoromethanesulphonyloxy ethylbromide with [¹⁸F]F⁻ and Seung-Jun *et al* Applied Radiation and Isotopes (1999), 51, 293-7 describes an analogous synthesis of 3-[¹⁸F]fluoropropylbromide. A similar method is described in Comagic *et al* Applied Radiation and Isotopes (2002), 56, 847-851 wherein 2-bromo-1-[¹⁸F]fluoroethane is prepared by nucleophilic displacement of 1,2-dibromoethane with [¹⁸F]F⁻. Solid-phase nucleophilic fluorination methods are described in co-pending International Patent Application PCT/GB02/02505.

20

In view of the importance of [¹⁸F]fluorohaloalkanes as radiolabelling reagents, there exists the need for synthetic methods for their preparation in good radiochemical yield and in which isolation of the product is more readily achievable. Furthermore, there is also a need for such synthetic methods which are amenable to automation.

25


In a first aspect, the invention provides a process for the production of an [¹⁸F]fluorohaloalkane which comprises treatment of a solid support-bound precursor of formula (I):

30

SOLID SUPPORT-LINKER-SO₂-O-(CH₂)_nX (I)

wherein n is an integer of from 1 to 7 and X is chloro, bromo, or iodo;

with $^{18}\text{F}^-$ to produce the $[^{18}\text{F}]$ fluorohaloalkane of formula (II)



wherein n and X are as defined for the compound of formula (I), optionally

5 followed by

- (i) removal of excess $^{18}\text{F}^-$, for example by ion-exchange chromatography; and/or
- (ii) removal of organic solvent.

10 Preferably, in the compounds of formula (I) above, n is an integer of 1 to 4, more

preferably, 1 or 2. In the compounds of formula (I) above, X is preferably bromo or iodo. Preferred $[^{18}\text{F}]$ fluorohaloalkanes of formula (II) prepared, include $[^{18}\text{F}]$ fluorobromomethane, $[^{18}\text{F}]$ fluoroiodomethane, $[^{18}\text{F}]$ fluorobromoethane, $[^{18}\text{F}]$ fluoroiodoethane, $[^{18}\text{F}]$ fluorobromopropane, and $[^{18}\text{F}]$ fluoroiodopropane.

15 As the $[^{18}\text{F}]$ fluorohaloalkane of formula (II) is removed from the solid-phase into solution, all unreacted precursor remains bound to the resin and can be separated by simple filtration, thus obviating the need for complicated purification, for example by HPLC. The $[^{18}\text{F}]$ fluorohaloalkane of formula (II) may be cleaned up by removal of excess F^- , for example by ion-exchange chromatography and/or

20 by removal of any organic solvent.


As shown in Scheme 1, the compound of formula (I) may be conveniently prepared from any sulphonic acid functionalised commercially available resin, such as Merrifield Resin, NovaSyn[®] TG Bromo Resin,

25 (Bromomethyl)phenoxyethyl polystyrene, or Wang Resin which may be reacted with a chlorinating agent to give the corresponding sulphonyl chloride resin. This may be carried out by treating the resin with, for example, phosphorus pentachloride, phosphorus trichloride, oxalyl chloride, or thionyl chloride, in an appropriate inert solvent such as dichloromethane, chloroform, or acetonitrile, and

30 heating at elevated temperature for a period of time. The excess reagent may then be removed from the resin by washing with further portions of the inert solvent. The sulphonyl chloride resin may then be reacted with the alcohol

analogue of the tracer to produce the resin-bound precursor of formula (I). This may be carried out by treating the resin with a solution of the alcohol in an inert solvent such as chloroform, dichloromethane, acetonitrile, or tetrahydrofuran containing a non-nucleophilic soluble base such as sodium hydride or a 5 trialkylamine, for example triethylamine or diisopropylethylamine. The reaction may be carried out at a temperature of 10 to 80°C, optimally at ambient temperature for a period of from around 1 to 24 hours. The excess alcohol and base may then be removed from the solid support by washing with further portions of an inert solvent such as chloroform, dichloromethane, or 10 tetrahydrofuran. Alternatively, the LINKER may be attached to the haloalkane, before being attached to the SOLID SUPPORT to form the compound of formula (I), using analogous chemistry to that described above.

15 Scheme 1







In the compounds of formula (I), the "SOLID SUPPORT" may be any suitable solid-phase support which is insoluble in any solvents to be used in the process 20 but to which the LINKER and/or haloalkane can be covalently bound. Examples of suitable SOLID SUPPORT include polymers such as polystyrene (which may be block grafted, for example with polyethylene glycol), polyacrylamide, or polypropylene or glass or silicon coated with such a polymer. The solid support may be in the form of small discrete particles such as beads or pins, or as a






coating on the inner surface of a cartridge or on a microfabricated vessel.

In the compounds of formula (I), the "LINKER" may be any suitable organic group which serves to space the reactive site sufficiently from the solid support structure

5 so as to maximise reactivity. Suitably, the LINKER comprises zero to four aryl groups (suitably phenyl) and/or a C₁₋₆ alkyl or C₁₋₆haloalkyl (suitably C₁₋₆ fluoroalkyl), and optionally one to four additional functional groups such as amide or sulphonamide groups. Examples of such linkers are well known to those skilled in the art of solid-phase chemistry, but include:



10



wherein at each occurrence, k is an integer of 0 to 3 and R^L is hydrogen or

C₁₋₆ alkyl.

Treatment of the compound of formula (I) with ¹⁸F⁻ may be effected by treatment with any suitable source of ¹⁸F⁻, such as Na¹⁸F, K¹⁸F, Cs¹⁸F, tetraalkylammonium ¹⁸F fluoride, or tetraalkylphosphonium ¹⁸F fluoride. To increase the reactivity of the fluoride, a phase transfer catalyst such as 4,7,13,16,21,24 hexaoxa-1,10-diazabicyclo[8.8.8] hexacosane may be added and the reaction performed in a non protic solvent. These conditions give reactive fluoride ions. The treatment with ¹⁸F⁻ is suitably effected in the presence of a suitable organic solvent such as acetonitrile, dimethylformamide, dimethylsulphoxide, tetrahydrofuran, dioxan, 1,2 dimethoxyethane, sulpholane, N-methylpyrrolidinone, at a non-extreme temperature, for example, 15°C to 180°C, preferably at elevated temperature. On completion of the reaction, the [¹⁸F]fluorohaloalkane of formula (II) dissolved in the solvent is conveniently separated from the solid-phase by filtration.

Any excess ¹⁸F⁻ may be removed from the solution of [¹⁸F]fluorohaloalkane by any suitable means, for example by ion-exchange chromatography or solid phase absorbents. Suitable ion-exchange resins include BIO-RAD AG 1-X8 or Waters QMA and suitable solid phase absorbents include alumina. The excess ¹⁸F⁻ may be removed using such solid phases at room temperature in aprotic solvents.


Any organic solvent may be removed by any standard method such as by evaporation at elevated temperature *in vacuo* or by passing a stream of inert gas such as nitrogen or argon over the solution.

According to a further aspect, the invention provides a process for the production of an [¹⁸F]fluorohaloalkane which comprises treatment of a solid support-bound precursor of formula (III):



wherein n and X are as defined for the compound of formula (I), and Y- is an anion (preferably trifluoromethylsulphonate (triflate) anion or tetraphenyl borate anion);

with $^{18}\text{F}^-$ to produce the $[^{18}\text{F}]\text{fluorohaloalkane}$ of formula (II)



5

wherein n and X are as defined for the compound of formula (III), optionally followed by

- (i) removal of excess $^{18}\text{F}^-$, for example by ion-exchange chromatography; and/or
- (ii) removal of organic solvent.

10




The compound of formula (III) may be conveniently prepared from a functionalised commercially available resin such as a Merrifield Resin or Wang Resin. Suitably, a hydroxyiodoaryl (such as an iodophenol) containing LINKER group is treated with an inorganic base, such as cesium carbonate and then added to the resin,

15 pre-swollen with an inert solvent, such as N,N-dimethylformamide and allowed to react at elevated temperature, for example 30 to 80°C. Excess reagents may be removed by washing the resin with further inert solvent. The resultant iodophenol functionalised resin may then be treated with a source of acetate anions (such as acetic acid, acetic anhydride, or acetyl chloride) in the presence of an oxidising

20 agent, such as hydrogen peroxide to provide the corresponding diacetoxy-iodophenyl functionalised resin. The diacetoxy-iodophenyl functionalised resin may then be stirred in an inert solvent, such as dichloromethane, in the presence of acid such as hydrochloric acid, trifluoromethane sulphonic acid, or acetic acid at a low temperature, suitably -40°C to 10°C before addition of the

25 fluorohaloalkane, suitably functionalised as a boronic acid or triorgano tin (suitably trialkyl tin) derivative which may be coupled to the resin at a non-extreme temperature. As in previous steps, the desired compound of formula (III) may be separated by filtration and washing with an inert solvent.

30 In the compound of formula (III), the LINKER is as defined above but suitably comprises an aryl group (suitably phenyl) adjacent to the I^+ . Preferred examples include:



Treatment of a compound of formula (III) with F^- , preferred haloalkanes in formula (III), removal of excess F^- and any organic solvent are all suitably as described for
 5 the compounds of formula (I) above.

The compounds of formula (I) and (III) are novel and thus form a further aspect of the present invention.

10 As described above, the advantages of such solid-phase processes for preparation of ^{18}F fluorohaloalkanes include the relative speed of the process, simplified purification methods and ease of automation- all of which mean that the processes are suitable for preparation of ^{18}F fluorohaloalkanes which can then be used to prepared ^{18}F -labelled tracers for use in PET. Accordingly, the present
 15 invention provides a process for the preparation of a ^{18}F fluorohaloalkane of formula (II) for use in PET chemistry.

Conveniently, the solid support bound precursor of formula (I) or (III) could be provided as part of a kit to a radiopharmacy, PET centre, or nuclear medicine
 20 department. The kit may contain a cartridge which can be plugged into a suitably adapted automated synthesiser. The cartridge may contain, apart from the solid support-bound precursor, a column to remove unwanted fluoride ion, and an

appropriate vessel connected so as to allow the reaction mixture to be evaporated and allow the product to be formulated as required. The reagents and solvents and other consumables required for the synthesis may also be included together with a compact disc carrying the software which allows the synthesiser to be 5 operated in a way so as to meet the customers requirements for radioactive concentration, volumes, time of delivery etc.

Conveniently, all components of the kit are disposable to minimise the possibilities of contamination between runs and may be sterile and quality assured.

10

The invention further provides a radiosynthesis kit for the preparation of an $[^{18}\text{F}]$ fluorohaloalkane for use in PET chemistry, which comprises:

- (i) a vessel containing a compound of formula (I) or (III); and
- (ii) means for eluting the vessel with a source of $^{18}\text{F}^-$; and
- 15 (iii) an ion-exchange cartridge for removal of excess $^{18}\text{F}^-$.

The invention further provides a cartridge for a radiosynthesis kit for the preparation of an $[^{18}\text{F}]$ fluorohaloalkane for use in PET chemistry which comprises:

- (i) a vessel containing a compound of formula (I) or (III); and
- 20 (ii) means for eluting the vessel with a source of $^{18}\text{F}^-$.


The invention will now be illustrated by way of the following Examples.

Example 1. Synthesis of $[^{18}\text{F}]$ -fluorobromomethane

25 Example 1(i) Preparation of perfluorobutane-1,4-bis-sulphonylchloride

(Following the method of Weiming Qiu and Donald J. Burton


Journal of fluorine chemistry, 60 (1993) 93-100.)



The mixture of 1,4 diiodoperfluorobutane ($I(CF_2)_4I$) (24.14g, 53.2mmol), sodium dithionite $Na_2S_2O_4$ (24g, 117.2mmol) and sodium hydrogen sulphate $NaHCO_3$ (12.8g, 152.4mmol) in water H_2O (36ml) / Acetonitrile CH_3CN (36ml) was stirred 5 at room temperature for 2 hours. It was filtered, and the filtrate was concentrated under reduced pressure to remove the acetonitrile. To the residue was added H_2O (100ml). The so obtained solution was vigorously stirred and treated with chlorine gas Cl_2 at $0^\circ C$ until the colour of I_2 disappeared. Dichloromethane CH_2Cl_2 (100ml) was added and the mixture vigorously shaken. The organic phase was separated, 10 and the aqueous phase was extracted with CH_2Cl_2 . The combined organic phase was washed with water H_2O , brine, and dried with sodium sulphate Na_2SO_4 and concentrated to afford a waxy yellow crystalline solid. (15.4g, 74%). Recrystallization from hexane afforded off-white needles of perfluorobutane-1,4- 15 bis-sulphonylchloride.

15 ^{19}F NMR ($CDCl_3$, $CFCl_3$ reference) δ : -104.4, -119.1.

Example 1(ii) Preparation of perfluorobutane-1,4-bis-sulphonate dipotassium salt




20 To the solution of potassium hydroxide KOH (9.8g, 5eq) in water H_2O (19ml) was added gradually perfluorobutane-1,4-bis-sulphonylchloride (14g, 35mmol) at $85^\circ C$ - $90^\circ C$ with stirring. After the addition, the reaction was continued for more 4 hours at the same temperature, and then it was cooled overnight. It was filtered and the solids was washed with a little of cooled water and dried in vacuum to give 25 perfluorobutane-1,4-bis-sulphonate dipotassium salt

19F NMR (CD_3OD , $CFCl_3$ reference) δ : -114.00, -120.11.


Example 1(iii) Preparation of perfluorobutane-1,4-bis-sulphonic acid

(Following the method described in US patent 4329,478, Fred E. Behr.)




5 Perfluorobutane-1,4-bis-sulphonate dipotassium salt (15g, 34.2mmol) was dissolved in hot water (100ml). It was added to an ion exchange column of Amberlyst 15 resin, (40x4cm) which had been previously washed with excess 6N HCl and rinsed with distilled water. The column was then washed slowly with distilled water, and the first 300ml of aqueous solution collected. The solution
 10 was concentrated in vacuum and the residue was dried under reduced pressure at 80°C to afford perfluorobutane-1,4-bis-sulphonic acid. (11.0g, 30mmol, 88%)
¹H NMR (CDCl₃) δ: 8.00
¹⁸F NMR (CDCl₃, CFCl₃ reference) δ: -114.7, -121.3.

15 Example 1(iv) Preparation of perfluorobutane-1,4-bis-sulphonic acid anhydride
 (Following the method described in US patent 4329,478, Fred E. Behr.)



20 Perfluorobutane-1,4-bis-sulphonic acid (11.0g, ~30mmol) was mixed with P₂O₅ (40g, ~10eq) and sand. The mixture was heated to 140-180°C and distilled under reduced pressure with dry-ice cooling collector to afford crude product (5.12g). Redistillation gives pure perfluorobutane-1,4-bis-sulphonic acid anhydride.
 25 ¹⁸F NMR (CDCl₃, CFCl₃ reference) δ: -105.7, -121.8.

Example 1(v) Synthesis of PS – 4-(Benzyl-ethyl-sulfonamide)octafluoro-butane-1-sulfonic acid




5 To a portion of the polystyrene resin (Novabiochem, Novasyn resin) (202mg), which had previously been swollen in dichloromethane (2ml) and then suspended in a further aliquot of dichloromethane (2ml) the perfluorobutyl-1,4-cyclic-sulfonic anyhydride (116mg, 5Eq) was added. Following this di-isopropylethyl amine (0.174 ml) was added and the suspension stirred overnight at room temperature. The
 10 solvent was removed by filtration and the resin washed with consecutive addition and filtration of dichloromethane (5 ml), methanol (5ml), DMF (5ml), water (5.ml), methanol (5 ml), and dichloromethane (5ml). The resulting resin was then treated with NaOH (1M) in THF/water (2 x 2ml) before washing with consecutive portions of methanol (5ml), dichloromethane (5ml) and methanol (5 ml) again. The resin
 15 was then dried under high vacuum.

Gel Phase ^{19}F NMR (referenced to CFCl_3 , 300K) : δ -121.0, -114.8, -113.4

Example 1(vi) Synthesis of PS – 4-(Benzyl-ethyl-sulfonamide)octafluoro-butane-1-sulfonyl chloride

20




A portion of the resin prepared in the manner of Example 1(v) above is swollen with dichloromethane (2ml) and then washed consecutively with HCl (1M) in

THF/water (10 x 5 ml) to give the free sulphonic acid. The resin is washed consecutively with dichloromethane, methanol and THF before drying under high vacuum.

5 The resin is then suspended in dichloromethane and to it is added in excess a common chlorinating agent such as phosphorous pentachloride, phosphorus trichloride or thionyl chloride. The suspension is stirred for 2 hours before filtration and then washing of the resin with dichloromethane and then THF.

10 Example 1(vii) Synthesis of fluorobromomethane precursor resin



A solution of bromomethanol in THF is added to a portion of the resin prepared as described in Example 1(vi) above which has previously been swollen in THF. To this is added a solution of potassium t-butoxide in tetrahydrofuran and the suspension is stirred overnight. After filtration the resin is washed consecutively with dichloromethane and THF before drying under high vacuum.

Example 1(viii) Radiofluorination to prepare [¹⁸F]-fluorobromomethane

20 To a portion of the resin (prepared as described in Example 1(vii)) held in a cartridge is added a solution in dry acetonitrile of kryptofix, potassium carbonate and [¹⁸F]-fluoride. The suspension is heated to 85°C for 10 minutes and then the solution is filtered off. The solution is then passed onto a C₁₈ solid phase extraction cartridge and washed with water to remove acetonitrile, kryptofix and potassium carbonate. Addition of more acetonitrile washes the radiofluorinated product of the cartridge into a solution of 0.1 M HCl. This solution is heated for 5 minutes before neutralization and analysis.

Claims

1. A process for the production of an $[^{18}\text{F}]$ fluorohaloalkane which comprises
 5 treatment of a solid support-bound precursor of formula (I):



wherein n is an integer of from 1 to 7 and X is chloro, bromo or iodo;
 with $^{18}\text{F}^-$ to produce the $[^{18}\text{F}]$ fluorohaloalkane of formula (II)



wherein n and X are as defined for the compound of formula (I), optionally followed by

(i) removal of excess $^{18}\text{F}^-$, for example by ion-exchange chromatography; and/or
 15 (ii) removal of organic solvent.

2. A process for the production of an $[^{18}\text{F}]$ fluorohaloalkane according to claim 1
 wherein n is an integer of 1 to 4, preferably 1 or 2.

20 3. A process for the production of an $[^{18}\text{F}]$ fluorohaloalkane according to claim 1
 or 2 wherein the compound of formula (II) prepared is selected from
 $[^{18}\text{F}]$ fluorobromomethane, $[^{18}\text{F}]$ fluoroiodomethane, $[^{18}\text{F}]$ fluorobromoethane,
 $[^{18}\text{F}]$ fluoroiodoethane, $[^{18}\text{F}]$ fluorobromopropane, and $[^{18}\text{F}]$ fluoroiodopropane

25 4. A compound of formula (I) as defined in claim 1:



wherein n is an integer of from 1 to 7 and X is chloro, bromo or iodo.

30 5. A compound of formula (I) according to claim 4 wherein n is an integer of from
 1 to 4, and is preferably 1 or 2.

6. A radiosynthesis kit for the preparation of an $[^{18}\text{F}]$ fluorohaloalkane for use in PET chemistry, which comprises:

(i) a vessel containing a compound of formula (I) as defined in any one of claims

5 1 to 3; and

(ii) means for eluting the vessel with a source of $^{18}\text{F}^-$; and

(iii) an ion-exchange cartridge for removal of excess $^{18}\text{F}^-$.

7. A cartridge for a radiosynthesis kit which comprises:

10 (i) a vessel containing a compound of formula (I) as defined in any one of claims

1 to 3; and

(ii) means for eluting the vessel with a source of $^{18}\text{F}^-$.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.